Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes

Nucleic Acids Research

Volumn 37, Issue 16, 2009, Pages 5432-5442

  Malina, Jaroslav ^a   Vrana, Oldrich ^a   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHLORODIETHYLENETRIAMINEPLATINUM CHLORIDE; CISPLATIN; DNA FRAGMENT; DNA TOPOISOMERASE; PLATINUM COMPLEX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHLORODIETHYLENETRIAMINE PLATINUM; CISPLATIN DNA ADDUCT; CISPLATIN-DNA ADDUCT; DNA; DRUG DERIVATIVE; ENZYME INHIBITOR;

ARTICLE; CATALYSIS; CHEMICAL REACTION; DNA ADDUCT; DNA CLEAVAGE; DNA REPLICATION; DRUG STRUCTURE; ELECTROPHORESIS; ENZYME ACTIVITY; GENE MAPPING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; CHEMISTRY; DNA SUPERCOILING; DRUG ANTAGONISM; METABOLISM;

EUKARYOTA;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; DNA ADDUCTS; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DNA, SUPERHELICAL; ENZYME INHIBITORS;

EID: 70449707728     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkp580     Document Type: Article

References (53)

1. Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev. Cancer, 7, 573-584.
2. Jung, Y. and Lippard, S.J. (2007) Direct cellular responses to platinum-induced DNA damage. Chem. Rev., 107, 1387-1407.
3. Brabec, V. and Kasparkova, J. (2002) Molecular aspects of resistance to antitumor platinum drugs. Drug Resist. Updates, 5, 147-161.
4. Brabec, V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol., 71, 1-68.
5. Bouayadi, K., Calsou, P., Pedrini, A.M. and Salles, B. (1992) In vitro evolution of cisplatin DNA monoadducts into diadducts is dependent upon superhelical density. Biochem. Biophys. Res. Commun., 189, 111-118.
6. Vrana, O., Boudny, V. and Brabec, V. (1996) Superhelical torsion controls DNA interstrand cross-linking by antitumor cis-diamminedichloroplatinum(II). Nucleic Acids Res., 24, 3918-3925.
7. Coleman, L.W., Rohr, L.R., Bronstein, I.B. and Holden, J.A. (2002) Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Human Pathol., 33, 599-607.
8. Palumbo, M., Gatto, B., Moro, S., Sissi, C. and Zagotto, G. (2002) Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim. Biophys. Acta, 1587, 145-154.
9. Ulukan, H. and Swaan, P.W. (2002) Camptothecins - a review of their chemotherapeutic potential. Drugs, 62, 2039-2057.
10. Neumann, S., Simon, H., Zimmer, C. and Quinones, A. (1996) The antitumor agent cisplatin inhibits DNA gyrase and preferentially induces gyrB gene expression in Escherichia coli. Biol. Chem., 377, 731 739.
11. Fukuda, M., Nishio, K., Kanzawa, F., Ogasawara, H., Ishida, T., Arioka,H., Bojanowski,K., Oka,M. and Saijo,N. (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res., 56, 789-793.
12. Masumoto, N., Nakano, S., Esaki, T., Fujishima, H., Tatsumoto, T. and Niho,Y. (1995) Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int. J. Cancer, 62, 70-75.
13. Kanzawa, F., Koizumi, F., Koh, Y., Nakamura, T., Tatsumi, Y., Fukumoto,H., Saijo,N., Yoshioka,T. and Nishio,K. (2001) In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin. Cancer Res., 7, 202-209.
14. Guichard, S., Arnould, S., Hennebelle, I., Bugat, R. and Canal, P. (2001) Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anti-Cancer Drugs, 12, 741-751.
15. Aoe, K., Kiura, K., Ueoka, H., Tabata, M., Chikamori, M., Kohara,H., Harada,M. and Tanimoto,M. (2004) Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res., 24, 3893-3897.
16. Tanaka, R., Ariyama, H., Qin, B.L., Shibata, Y., Takii, Y., Kusaba,H., Baba,E., Mitsugi,K., Harada,M. and Nakano,S. (2005) Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol. Rep., 14, 683-688.
17. Kobayashi, S., Furukawa, M., Dohi, C., Hamashima, H., Arai, T. and Tanaka,A. (1999) Topology effect for DNA structure of cisplatin: topological transformation of cisplatin-closed circular DNA adducts by DNA topoisomerase I. Chem. Pharm. Bull., 47, 783-790.
18. van Waardenburg, R.C.A.M., de Jong, L.A., van Eijndhoven, M.A.J., Verseyden, C., Pluim, D., Jansen,L.E.T., Bjornsti,M.-A. and Schellens,J.H.M. (2004) Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J. Biol. Chem., 279, 54502-54509.
19. Fichtinger-Schepman, A.M.J., Van der Veer, J.L., Den Hartog, J.H.J., Lohman, P.H.M. and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 24, 707-713.
20. Brabec, V., Kleinwächter, V., Butour, J.L. and Johnson, N.P. (1990) Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem., 35, 129-141.
21. Andersen, A.H., Gocke, E., Bonven, B.J., Nielsen, O.F. and Westergaard, O. (1985) Topoisomerase-I has a strong binding preference for a conserved hexadecameric sequence in the promotor region of the ribosomal-RNA gene from Tetrahymena-Pyriformis. Nucleic Acids Res., 13, 1543-1557.
22. Bonven, B.J., Gocke, E. and Westergaard, O. (1985) A high-affinity topoisomerase-1 binding sequence is clustered at DNase-1 hypersensitive sites in Tetrahymena R-chromatin. Cell, 41, 541-551.
23. Pommier, Y., Kohlhagen, G., Kohn, K.W., Leteurtre, F., Wani, M.C. and Wall,M.E. (1995) Interaction of an alkylating camptothecin derivative with a DNA-base at topoisomerase I-DNA cleavage sites. Proc. Natl Acad. Sci. USA, 92, 8861-8865.
24. Brabec, V., Reedijk, J. and Leng, M. (1992) Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry, 31, 12397-12402.
25. Kasparkova, J., Mellish, K.J., Qu, Y., Brabec, V. and Farrell, N. (1996) Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies. Biochemistry, 35, 16705-16713.
26. Brabec, V. and Leng, M. (1993) DNA interstrand cross-links of transiamminedichloroplatinum(II) are preferentially formedbetween guanine and complementary cytosine residues. Proc. Natl Acad. Sci. USA, 90, 5345-5349.
27. Maxam, A.M. and Gilbert, W. (1980) Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol., 65, 499-560.
28. Novakova, O., Kasparkova, J., Vrana, O., van Vliet, P.M., Reedijk, J. and Brabec,V. (1995) Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry, 34, 12369-12378.
29. Keck, M.V. and Lippard, S.J. (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes. J. Am. Chem. Soc., 114, 3386-3390.
30. Verma, R.P. and Hansch, C. (2009) Camptothecins: A SAR/QSAR study. Chem. Rev., 109, 213-235.
31. Nagarajan, M., Morrell, A., Ioanoviciu, A., Antony, S., Kohlhagen, G., Agama,K., Hollingshead,M., Pommier,Y. and Cushman,M. (2006) Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J. Med. Chem., 49, 6283-6289.
32. Pourquier, P., Pilon, A.A., Kohlhagen, G., Mazumder, A., Sharma, A. and Pommier,Y. (1997) Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps - importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem., 272, 26441-26447.
33. Pourquier, P., Ueng, L.M., Fertala, J., Wang, D., Park, H.J., Essigmann,J.M., Bjornsti,M.A. and Pommier,Y. (1999) Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages - 7,8-dihydro-8-oxoguanine and 5-hydroxycytosine. J. Biol. Chem., 274, 8516-8523.
34. Redinbo, M.R., Champoux, J.J. and Hol, W.G.J. (2000) Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry, 39, 6832-6840.
35. Pommier, Y., Kohlhagen, G., Laco, G.S., Kroth, H., Sayer, J.M. and Jerina,D.M. (2002) Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem., 277, 13666-13672.
36. Zaludova, R., Kleinwächter, V. and Brabec, V. (1996) The effect of ionic strength on melting of DNA modified by platinum(II) complexes. Biophys. Chem., 60, 135-142.
37. Johnson, N.P., Macquet, J.-P., Wiebers, J.L. and Monsarrat, B. (1982) Structures of adducts formed between [Pt(dien)Cl]Cl and DNA in vitro. Nucleic Acids Res., 10, 5255-5271.
38. Cohen, S.M., Mikata, Y., He, Q. and Lippard, S.J. (2000) HMG-Domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts. Biochemistry, 39, 11771-11776.
39. Lock, R.B. and Ross, W.E. (1987) DNA topoisomerases in cancer therapy. Anti-Cancer Drug Des., 2, 151-164.
40. Chen, A.Y. and Liu, L.F. (1994) DNA topoisomerases:Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34, 191-218.
41. Gupta, M., Fujimori, A. and Pommier, Y. (1995) Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta, 1262, 1-14.
42. Capranico, G. and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta, 1400, 185-194.
43. Liu, L.F., Desai, S.D., Li, T.K., Mao, Y., Sun, M. and Sim,S.P. (2000) Mechanism of action of camptothecin. Ann. NY Acad. Sci., 922, 1-10.
44. Been, M.D., Burgess, R.R. and Champoux, J.J. (1984) Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res., 12, 3097-3114.
45. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K. and Pommier, Y. (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem., 266, 20418-20423.
46. Tanizawa, A., Kohn, K.W. and Pommier, Y. (1993) Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res., 21, 5157-5166.
47. Cohen, G.L., Ledner, J.A., Bauer, W.R., Ushay, H.M., Caravana, C. and Lippard,S.J. (1980) Sequence dependent binding of cis-dichlorodiammineplatinum(II) to DNA. J. Am. Chem. Soc., 102, 2487-2488.
48. Tullius, T.D. and Lippard, S.J. (1982) Ethidium bromide changes the nuclease-sensitive DNA binding sites of the antitumor drug cis-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA, 79, 3489-3492.
49. Kjeldsen, E., Svejstrup, J.Q., Gromova, I.I., Alsner, J. and Westergaard, O. (1992) Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol., 228, 1025-1030.
50. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J. and Hol, W.G.J. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504-1513.
51. Ward, B., Rehfuss, R., Goodisman, J. and Dabrowiak, J.C. (1988) Rate enhancements in the DNase I footprinting experiment. Nucleic Acids Res., 16, 1359-1369.
52. Goodisman, J. and Dabrowiak, J.C. (1992) Structural changes and enhancements in DNase I footprinting experiments. Biochemistry, 31, 1058-1064.
53. Jamieson, E.R. and Lippard, S.J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 99, 2467 2498.